The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2024 | The importance of understanding cellular functionality to develop biological therapies for CLL
Francesco Forconi, MD, DM, PhD, FRCPath, University of Southampton, Southampton, UK, discusses the shift in treatment for chronic lymphocytic leukemia (CLL) from intensive immunochemotherapy to biological therapies, emphasizing the importance of two key biological pillars: B-cell receptor signaling and anti-apoptotic mechanisms. He argues that understanding the functional behavior of cells is crucial for developing novel therapies, which may not solely rely on genetics. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
